Every DEF 14A that Firefly Neuroscience, Inc. (AIFF) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow AIFF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIFF filings page.
Firefly Neuroscience, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on August 5, 2026 at 10 a.m. Eastern Time. Stockholders of record as of June 8, 2026, when 15,604,571 common shares were outstanding, are entitled to vote.
Proposals include electing Class III directors, ratifying CBIZ Canada, LLP as independent auditor for 2026, an advisory say-on-pay vote on named executive officer compensation, and approving Amendment No. 2 to the 2024 Long-Term Incentive Plan. Stockholders are also asked to approve a Certificate of Amendment to decrease the total number of authorized shares and to approve a potential adjournment of the meeting if more time is needed to solicit proxies.
The proxy details Board composition, independence, and committee structures, and discloses 2025 compensation, including $1,063,718 for CEO Greg Lipschitz and $748,335 for President and COO David DeCaprio. Directors and executive officers as a group beneficially own 6.90% of outstanding common stock.
Firefly Neuroscience (AIFF) amended its definitive proxy to set a single, fixed increase in authorized capital for a stockholder vote. Proposal 4 now asks to raise total authorized shares from 101,000,000 to 5,001,000,000, consisting of 5,000,000,000 Common Stock and 1,000,000 Preferred Stock, via a Certificate of Amendment filed after approval. The revision removes any prior range or Board discretion to pick a number, aligning with Delaware law.
The company states this capacity supports future financing, acquisitions, partnerships, and other corporate purposes. The filing notes potential dilution from future issuances. As of the record date, 13,448,848 shares of Common Stock were outstanding. Proposal 4 is treated as a routine matter; brokers may vote without instructions, and for Proposals 3 and 4, abstentions and broker non-votes have no effect. Approval requires a majority of votes cast. The Board may abandon the amendment before filing even if approved.
Firefly Neuroscience, Inc. (AIFF) is soliciting proxies for its 2025 Annual Meeting to be held virtually at 10:00 a.m. ET on October 27, 2025. The Board recommends votes FOR five proposals: elect two Class II directors (nominees Brian Posner and Stella Vnook), ratify appointment of Marcum as independent auditor for fiscal 2025, approve an amendment to the equity incentive plan to add 317,820 shares and an annual automatic increase (lower of 4% of outstanding common stock or Board-determined amount) from January 1, 2026 through January 1, 2035, authorize the Board to increase authorized shares up to an aggregate of 5,001,000,000 (including 1,000,000 preferred shares), and allow adjournment if needed to solicit additional proxies. Materials including the 2024 Form 10-K are available at www.proxyvote.com and the virtual meeting website. The proxy describes Board composition, committee charters, indemnification and director compensation (option awards for non-employee directors), and discloses pay-versus-performance information noting that net loss increased from 2023 to 2024 while compensation actually paid (CAP) to NEOs increased. Voting methods (Internet, mail, virtual) and quorum/broker-vote rules are explained.